A Multicenter, Phase II study to assess the response rate of subjects with newly diagnosed Multiple Myeloma when treated with Carfilzomib (Kyprolis),Cyclophosphamide and Dexamethasone as induction followed by an autologous bone marrow transplant and Carfilzomib (Kyprolis), Thalidomide and Dexamethasone as consolidation.

Trial Profile

A Multicenter, Phase II study to assess the response rate of subjects with newly diagnosed Multiple Myeloma when treated with Carfilzomib (Kyprolis),Cyclophosphamide and Dexamethasone as induction followed by an autologous bone marrow transplant and Carfilzomib (Kyprolis), Thalidomide and Dexamethasone as consolidation.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms KIWI
  • Sponsors Onyx Pharmaceuticals
  • Most Recent Events

    • 15 Feb 2017 Planned End Date changed from 2 Nov 2017 to 28 Feb 2018.
    • 15 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 08 Jun 2016 Planned initiation date changed from 30 Mar 2015 to 2 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top